[Association between lysosomal cysteine protease cathepsin's activation and left ventricular function and remodeling

Xian-Wu Cheng1, Jie Zhang, Hui Song

  • 1Department of Cardiovascular Research Medicine, Nagoya University School of Medicine, Aichiken, Nagoya 466-8550, Japan. xianwu@med.nagoya-u.ac.jp

Insights

Cathepsin S (Cat S) expression and activity increase in hypertensive heart failure, contributing to myocardial remodeling. Targeting Cat S may offer a new therapeutic strategy for heart failure.

Area of Science:

  • Cardiovascular Biology
  • Enzymology
  • Pathophysiology

Context:

  • Hypertension leads to cardiac remodeling and heart failure.
  • The role of specific proteases in this process is not fully understood.
  • Cathepsin S (Cat S) is a cysteine protease implicated in various biological functions.

Purpose:

  • To investigate the expression and activity of Cat S in the myocardium of rats with hypertension-induced heart failure.
  • To examine the correlation between Cat S and cardiac function.
  • To explore the potential role of Cat S in myocardial remodeling.

Summary:

  • Cat S mRNA and activity were significantly upregulated in the left ventricular myocardium of rats with heart failure compared to hypertrophy or control groups.
  • Cat S expression negatively correlated with left ventricular ejection fraction (LVEF).
  • Increased Cat S activity was associated with elastic lamina fragmentation and elevated interleukin-1 beta levels, suggesting a role in myocardial remodeling.

Impact:

  • Cathepsin S (Cat S) is implicated in the pathogenesis of myocardial remodeling and heart failure.
  • Cat S may represent a novel therapeutic target for preventing or reversing hypertension-induced left ventricular remodeling and heart failure.
  • Findings were corroborated in human myocardial specimens.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...